molecules of the month


pro-mitotic selective MPS1 kinase inhibitor

dev. paused for 2nd candidate (BAY1217389)

from 2M cmpd biochem. HTS and SBDD

J. Med. Chem., Apr. 27, 2020

Bayer AG, Berlin, DE

1 min read

BAY1161909 is one of two clinical candidates disclosed in a single paper from Bayer. The compounds have an interesting anti-cancer mechanism – rather than inhibiting cancer cell growth, they accelerate cancer cell cycle progression, leading to cell death due to a high degree of chromosomal misaggregation. 909 was discovered through an HTS and optimization campaign, while the second candidate was developed from a known starting point. Development on 909 appears to have been paused in favor of the second candidate.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: